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A highly attenuated, recombinant rabies virus (RV) vaccine strain-based vector was utilized as a new immunization strategy
to induce humoral and cellular responses against hepatitis C (HCV) glycoprotein E2. We showed previously that RV-based
vectors are able to induce strong immune responses against human immunodeficiency virus type I (HIV-1) antigens. Here we
constructed and characterized three replication-competent RV-based vectors expressing either both HCV envelope proteins
E1 and E2 or a modified version of E2 which lacks 85 amino acids of its carboxy terminus and contains the human CD4
transmembrane domain and the CD4 or RV glycoprotein cytoplasmic domain. All three constructs stably expressed the
respective protein(s) as indicated by Western blotting and immunostaining. Moreover, surface expression of HCV E2 resulted
in efficient incorporation of the HCV envelope protein regardless of the presence of the RV G cytoplasmic domain, which was
described previously as a requirement for incorporation of foreign glycoproteins into RV particles. Killed and purified RV
virions containing HCV E2 were highly immunogenic in mice and also proved useful as a diagnostic tool, as indicated by a
specific reaction with sera from HCV-infected patients. In addition, RV vaccine vehicles were able to induce cellular
responses against HCV E2. These results further suggest that recombinant RVs are potentially useful vaccine vectors against
important human viral diseases. © 2002 Elsevier Science
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Hepatitis C virus (HCV) is the primary etiological agent
of non-A, non-B hepatitis affecting approximately 170
million people worldwide (Alter, 1997). The majority of
patients (70%) develop chronic hepatitis and a third of
these cases progress to liver cirhossis. All infected indi-
viduals have an increased risk of hepatocellular carci-
noma (Aihara and Miyazaki, 1998). Current treatments
include alpha interferon (INF-a) therapy alone or in con-
junction with ribavirin, but these treatments are expen-
sive, show a relatively low rate of response, and carry the
potential for significant side effects (Fried and
Hoofnagle, 1995). Therefore, the development of a pro-
tective HCV vaccine is a high priority. The task of devel-
oping an HCV vaccine is a difficult one for several rea-
sons. First of all, the broad genetic heterogeneity of the
virus has resulted in six known genotypes (Simmonds et
al., 1994), and the virus can exist in any given individual
as a population of closely related variants known as
quasispecies. Additionally, viral persistence may be cor-
related with the emergence of variants which have the
ability to evade the immune system (Major et al., 1999;
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24Weiner et al., 1992b). Lastly, protection from reinfection
may not occur even if an acute HCV infection has been
cleared by the immune system (Farci et al., 1992; Prince
et al., 1992).
HCV is a small, enveloped positive strand RNA virus of
the Flaviviridae family (Clarke, 1997). The 9.6-kb genome
consists of a 59 nontranslated region (NTR) which con-
tains an internal ribosome entry site (IRES) to begin
translation of the viral polyprotein (Le, Siddiqui, and
Maizel, 1996), which is cleaved by both host and viral
proteases to yield four structural and six nonstructural
(NS) proteins (Reed and Rice, 1998). The genome en-
codes two envelope glycoproteins, E1 and E2, which are
released from the polyprotein via signal peptidase cleav-
ages (Grakoui et al., 1993). Both proteins are largely
modified by N-linked glycosylation and are thought to be
type I integral transmembrane proteins with C-terminal
hydrophobic anchor domains. Expression of both the
glycoproteins in mammalian cell lines illustrates their
retention in the endoplasmic reticulum (ER) with no sur-
face expression detectable (Duvet et al., 1998). The E2
glycoprotein contains two hypervariable regions (HVR),
with HVR1 located at amino acid positions 390–410, and
HVR2 located at positions 474–480 (Weiner et al., 1991).
Antibodies directed against the HVR1 of E2 have been
implicated in controlling HCV infection (Kato et al., 1993).
In addition, the HVR1 of E2 contains both B cell and
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tibodies specifically directed at this region reportedly
blocked viral attachment in susceptible cells further im-
plicating E2 as responsible for viral attachment to the
host cell (Kojima et al., 1994; Leroux-Roels et al., 1996;
Lesniewski et al., 1995). However, there are conflicting
data regarding the clinical importance of sequence vari-
ation in the HVR1 of E2. One study indicates that the
evolutionary dynamics of HCV quasispecies predict
whether an infection will resolve itself or become chronic
(Farci et al., 2000), whereas another study concludes that
variations within the HVR1 of E2 does not correlate with
disease progression (Forns et al., 2000b). Overall, the
characteristics of the E2 glycoprotein render it an attrac-
tive target for a protective vaccine.
To date, HCV vaccine studies involving E2 have uti-
lized several strategies in a murine model including
purified recombinant antigens, DNA immunization (Gor-
don et al., 2000), DNA priming in conjunction with recom-
binant viruses such as Semliki Forest virus and canary-
pox (Pancholi et al., 2000; Vidalin et al., 2000), DNA
priming with recombinant protein boosting (Song et al.,
2000), replication-deficient recombinant adenovirus
(Makimura et al., 1996), and plasmid DNA immunization
(Inchauspe, 1999). Each of these strategies has experi-
enced limited success in producing both a humoral and
cellular immune response. Overall, E2 generates a po-
tent antibody response, but a weak CTL response in
mice in contrast to the core protein (Saito et al., 1997) or
nonstructural proteins (Gordon et al., 2000). One poten-
tial reason E2 has not generated a significant CTL re-
sponse in previous studies is the form of the protein that
is presented or encoded. Recent work by Flint et. al.
(2000) indicates that a monomeric form of the truncated
E2 glycoprotein (E2661) preferentially binds CD81, the pur-
ported cellular receptor for HCV, as compared to the
aggregated form of E2661. Additionally, intracellular forms
of E2661 bind CD81 with greater affinity than extracellular
forms.
Rabies virus (RV) is a negative-stranded RNA virus of
the Rhabdoviridae family with a simple genome organi-
zation coding for five structural proteins (Rose and Schu-
bert, 1987). Previous work indicates that RV is a suitable
expression vector with potential use as a viral vaccine
vector (Schnell et al., 1994). In addition, recombinant RV
expressing HIV-1 antigens elicited strong humoral and
CTL responses in immunized mice (McGettigan et al.,
2001a; Schnell et al., 2000).
Here we describe the expression of HCV glycopro-
teins by RV-based vectors and test the ability of these
vectors to induce an immune response to HCV. We
cloned the coding region of the HCV glycoproteins or a
modified version of E2 which lacks 85 amino acids of its
carboxy terminus and contains the human CD4 trans-
membrane domain (TMD) and the CD4 or RV glycopro-
tein (G) cytoplasmic domain (CD). The resulting recom-binant RVs stably expressed the respective HCV glyco-
proteins in addition to the other RV proteins and elicited
both humoral and cellular immune responses in immu-
nized mice.
RESULTS
Construction of recombinant RVs expressing HCV
structural proteins
E1 and E2 are supposed to be present on the surface
of HCV virions (Dubuisson, 2000) and therefore these
proteins are likely important neutralization targets. In
addition, the HCV E2 has been reported to interact with
CD81, a potential receptor for HCV (Pileri et al., 1998).
These findings suggest E1 and E2 of HCV may be im-
portant targets for both cellular and humoral responses.
We therefore decided to include these proteins in an
initial approach to analyze a Rhabdovirus-based vector
as a potential HCV vaccine. To generate RV recombinant
viruses we used a RV vaccine strain-based vector with a
new RV transcription unit, containing a RV stop/start
signal and two single sites (Fig. 1). The gene encoding
the HCV E1, E2, and p7 proteins to be expressed from
SPBN were generated by PCR and cloned between the
BsiWI and NheI sites resulting in the plasmid pSPBN-
E1E2p7. To analyze if the expression of the HCV E2 on
the surface of the infected cell enhances its immunoge-
nicity, two similar RV recombinant viruses containing the
gene encoding the ectodomain of HCV E2, lacking its
carboxy-terminal 85 amino acids, fused to the transmem-
brane domain (TMD) and cytoplasmic domain (CD) of
human CD4 (CD4), or the TMD of CD4 and the CD of RV
G were also PCR amplified. The resulting PCR products
were cloned utilizing the BsiWI/NheI sites to pSPBN
resulting in pSPBN-E2CD4 and pSPBN-E2CD4G (Fig. 1).
The pSPBN-E2CD4G was constructed on the basis of a
previous finding that the RV CD is required for incorpo-
ration of a foreign glycoprotein into RV virions (Mebat-
sion and Conzelmann, 1996; Mebatsion et al., 1997). An
RV viral particle containing HCV E2 would be helpful to
examine if recombinant killed RV virions are able to
induce E2-specific seroconversion and therefore are
useful as potential HCV vaccines.
As shown previously, RV vectors are able to stably
express large foreign genes (McGettigan et al., 2001a;
Mebatsion et al., 1996; Schnell et al., 2000), and thus, we
did not anticipate problems to recover the recombinant
RVs. As expected, infectious RVs were detected in tissue
culture supernatants of cells transfected by standard RV
recovery protocols for pSPBN, pSPBN-E1E2p7, pSPBN-
E2CD4, and pSPBN-E2CD4G (Finke and Conzelmann,
1999). In contrast to the previously constructed recombi-
nant RVs expressing HIV-1 gp160 (Schnell et al., 2000),
the recombinant RVs expressing HCV proteins grew at
8least to the same titers as SPBN, which were at least 10
foci-forming units (ffu).
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The HCV envelope proteins E1 and E2 interact to form
a noncovalent heterodimeric complex, which is retained
in the endoplasmic reticulum (ER), whereas a chimeric
HCV E2 protein containing the transmembrane domain
(TMD) and cytoplasmic domain (CD) of CD4 is trans-
ported to the cell surface (Dubuisson, 2000). To ensure
that the replacement of the CD of E2CD4 with that of RVG
did not interfere with the surface expression of the re-
combinant protein, BSR cells were infected with SPBN-
E1E2p7 (Fig. 2, Panels A, A9, A0), SPBN-E2CD4G (Fig. 2,
Panels B, B9, B0), or SPBN (Fig. 2, Panels C, C9 C0) at an
m.o.i. of 0.1 and fixed 48 h later with paraformaldehyde.
Infected cells were analyzed directly by immunofluores-
cence microscopy with a monoclonal antibody directed
against HCV E2 (Fig. 2 panels A9, B9, C9) or permeabilized
with Triton X-100 for internal staining with an antibody
against HCV E2 (Fig. 2 panels A, B, C) or RV N protein
(Fig. 2 panels A0, B0, C0). These results indicate that the
chimeric E2 protein containing the CD TMD and the RV
G CD is transported to the surface of the infected cell. In
addition, the finding that the conformation-sensitive
monoclonal antibody used for the immunostaining rec-
ognized the recombinant HCV E2, suggests that the
protein is properly folded.
To analyze the expression and processing of HCV E1
and E2 expressed by the recombinant viruses, lysates
from cells infected with recombinant RVs were separated
by SDS-PAGE under reducing conditions and analyzed
by Western immunoblotting with antibodies directed
against HCV E2 or E1. As illustrated in Fig. 3, lane 2, two
bands of the expected size for the uncleaved precursor
of the E1E2 polyprotein and the cleaved E2 can be
FIG. 1. Construction of recombinant RV genomes. At the top (A), the S
site-directed mutagenesis and a PCR strategy, a transcription stop/sta
(SmaI, PacI, BsiWI, and NheI). The HCV proteins (blue box) were intro
pSBPN-E1E2p7 (B), pSPBN-E2CD4 (C), and pSPBN-E2CD4G (D). E2CD
their C terminus, fused to the TMD (green box), and CD of human CDdetected in cell lysates infected with SPBN-E1E2p7 with
an HCV E2 specific monoclonal antibody H-52. A bandsimilar in size to the E2 expressed by SPBN-E1E2p7 in
lysates from SPBN-E2CD4 and SPBN-E2CD4G infected
cells. In addition, a more diffuse, slow-migrating band,
which was not observed for wild-type E2, was detected
for both chimeric E2 proteins containing a TMD and CD.
Previous experiments by Dubuisson and co-workers
suggested that the slower-migrating band of E2 corre-
sponds to molecules having their glycans processed by
Golgi enzymes and which are no longer retained in the
endoplasmic reticulum (ER) (Cocquerel et al., 2000). It is
interesting to note that only the slower migrating form of
E2 is incorporated into RV virions (Fig. 4, lanes 5 and 6)
supporting the theory that these molecules reach the cell
surface, whereas the faster migrating band is retained in
the ER. Immunoblotting with the monoclonal antibody A4
directed against HCV E1 (Dubuisson et al., 1994) de-
tected a band of about 27 kD as expected for HCV E1
only in cell lysates infected with the recombinant RV
SPBN-E1E2p7 (Fig. 3, lanes 6 and 10), confirming the
cleavage of the E1E2p7 precursor protein even in a
nonhuman cell line. Infection with all four recombinant
RVs was confirmed with a human polyclonal serum di-
rected against RV G protein (data not shown).
Recombinant HCV E2 is incorporated into RV virions
One goal of this study was to determine if it was
possible to incorporate chimeric E2 into RV virions. A
recombinant virion containing HCV E2 may be useful for
both producing E2 antigen for diagnostic use and as a
killed vaccine against HCV. To analyze incorporation of
the chimeric E2 proteins into RV particles, BSR cells
were infected with SPBN, SPBN-E2CD4, and SPBN-
E2CD4G with a m.o.i. of 0.1. Three days after infection,
ctor derived from the RV vaccine strain SAD B19 is illustrated. Through
al was introduced in addition to four unique restriction enzyme sites
into pSPBN using the BsiWI and NheI sites resulting in the plasmids
2CD4G are a truncated version of HCV E2 lacking 85 amino acids at
blue box) or TMD of CD4 and CD of RV G (red box), respectively.PBN ve
rt sign
ducedvirus was purified from the supernatants of infected cells
by a 20 to 70% density sucrose gradient. Viral proteins
.o.i. of
y direc
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sie blue staining. The results in Fig. 4 (lanes 1–3) showed
equal amounts and the same pattern of the RV proteins
for all three recombinant viruses, but no additional pro-
tein of the expected size for the HCV E2 could be de-
tected in the viral particles. The lack of detection of E2
may be due to E2 incorporation at low levels or it is
running as a more diffuse band then the other RV pro-
teins due to multiple O- and N-linked glycans. We there-
fore analyzed the recombinant virions by Western blot-
ting with an antibody directed against E2 and readily
detected the recombinant E2 in both SPBN-E2CD4 and
SPBN-E2CDG particles (Fig. 4, lanes 5 and 6), whereas
no signal was detected for SPBN (Fig. 4, lane 4) or
SPBN-E1E2p7 (data not shown). It was surprising that
both E2CD4 and E2CD4G were incorporated into RV
particles because an earlier finding by Mebatsion et al.
(1996) indicated that the RV G CD is a requirement for
incorporation of a foreign glycoprotein into RV virions
(Mebatsion et al., 1996). This is not the case for HCV E2
FIG. 2. Immunofluorescence studies of recombinant RVs expressin
E1E2p7 (A, A9, A0), SPBN-E2CD4G (B, B9, B0), or SPBN (C, C9, C0) at a m
A0, B0, C0) or not (A, B, and C), and stained with a monoclonal antibodand quantification indicated that the content of the re-
combinant E2CD4 was at least 60% of E2CD4G.The presence of the RV G CD in the HCV envelope
protein expressed by SPBN-E2CD4G was also verified
by Western blotting with an antibody specific for the RV
G CD. Pilot studies with this antibody showed that re-
combinant E2CD4G is comigrating with RV G, which
made it impossible to distinguish between the two pro-
teins. Because RV G contains only three to four N-linked
glycosylation sites but HCV E2 is heavily O- and N-
glycosylated, we decided to remove the N-glycan chains
by digestion of the RV virions with N-glycosidase F. As
illustrated in Fig. 4, lanes 7–9, the anti-RV G antibody
detected a band of similar size and intensity in the
expected size of deglycosylated RV G, whereas two
prominent additional bands are only detected in virions
containing E2 envelope protein with the RV G.
Reactivity of recombinant RV virions with human sera
We next analyzed whether the chimeric HCV E2 in the
recombinant particles is displayed in such a way that it
proteins. BSR cells were infected with the recombinant RVs SPBN-
0.1 and 48 h after infection, cells were fixed, permeabilized (A9, B9, C9,
ted against E2 (A, A9; B, B9; C, C9) or RV N (A0, B0, or C0).g HCVcan be recognized by sera of HCV-positive patients.
Recombinant HCV E2 is mostly produced by transfection
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form of HCV E2 which is secreted in the tissue culture
supernatant. In both cases, only small amounts of pro-
tein are produced. On the other hand, recombinant RVs
are easy to grow and purify and 1 mg RV G protein can
be extracted from 1 liter of tissue supernatants of RV
infected cells. In addition, RV virions can easily be de-
activated before purification and therefore handling in-
fectious material is limited to the growth of the viruses.
To analyze the antigenicity of the recombinant RV parti-
cles containing HCV E2, ELISA plates were coated with
recombinant HCV E2 glycoprotein derived from purified
SPBN-E2RVG virions. The results in Fig. 5 indicate that
the sera from three randomly chosen HCV-positive pa-
tients had high E2-specific ELISA titers between 1:400 to
1:1,600 (Fig. 5, HCV1-3), whereas pooled human control
sera from HCV- and RV-negative donors and a serum
from a HIV-1-positive patient did not react (see Fig. 5). A
control serum from a RV-vaccinated person showed a
similar ELISA titer, as demonstrated for the sera HCV-
positive patients due to the presence of RV G in addition
to the recombinant E2 in the viral envelope (Fig. 5,
HCV2/RV1). Of note, all sera except the one from the RV
vaccinated donor did not react on control ELISA plates
coated with SPBN-derived glycoprotein. These results
indicate that recombinant RVs can be used as quick easy
tools to screen for seroconversion against E2 of HCV-
infected individuals.
Recombinant RVs expressing HCV glycoproteins are
immunogenic in mice
We next wanted to determine whether recombinant
FIG. 3. Western blot analysis of HCV proteins expressed by RV. BSR
cells were infected with recombinant RVs as indicated (SPBN, SPBN-
E1E2p7, SPBN-E2CD4, SPBN-E2CD4G at a m.o.i. of 5. Cell lysates were
separated by SDS-PAGE and transferred to a nitrocellulose membrane.
Blots were probed with monoclonal antibodies directed against the
HCV E1 and E2 glycoproteins as indicated (a-E1, a-E1 1 E2, or a-E1).RVs expressing HCV glycoprotein(s) are immunogenic in
mice. The immune responses which may protect hu-mans from HCV infection are not well defined, but it is
likely that both cellular and humoral responses will be
required for protection of infection or clearence of HCV.
To analyze the immunogenicity of our RV vector express-
ing HCV proteins, we infected a group of 10 female
BALB/c mice with 1 3 107 ffu of SPBN-E2RVG, and a
group of five mice with an equal amount of the RV vector
SPBN, and left five mice uninfected. Fourteen days
postimmunization, all mice were bled and sera analyzed
by ELISA using recombinant HCV E2, but no E2-specific
antibodies were detected. Our previous experiments
with recombinant RVs expressing HIV-1 gp160 indicated
that the induction of a humoral response against HIV-1
gp160 required a boost with recombinant HIV-1 gp120
(Schnell et al., 2000). We therefore decided to apply a
boost vaccination using killed RV particles derived from
SPBN-E2RVG infected cells as a source of recombinant
HCV E2. A group of five mice primed with live SPBN-
E2CD4G and boosted with killed SPBN particles served
as a control. Ten days later, mice were bled and sera
analyzed by an HCV-specific ELISA. We expected to
detect serocoversion against E2 in the sera of mice
primed with live SPBN-E2CD4G and boosted with killed
SPBN-E2CD4G, but in only two out of five mice were
E2-specific antibodies detected. Of note, no adjuvant
was used for the immunization with the killed virions,
which may explain why only a portion of the mice devel-
oped antibodies directed against HCV E2. To analyze if a
second inoculation with the same killed RV virions would
induce a higher rate of serocoversion against HCV E2,
mice of each group recived a second immunization with
the same killed virions as used for the first one. Ten days
FIG. 4. Incorporation of HCV proteins in recombinant RVs. Purified
particles of SPBN, SPBN-E2CD4, or SPBN-E2CD4G were separated by
SDS-PAGE and visualized by Coomassie blue staining (CB, lanes 1, 2,
3) or transferred to a nitrocellulose membrane before (a-E2) or after
digestion with N-glycosidase F (a-RV-G-tail). Blots were probed with
monoclonal antibodies directed against the HCV E2 (a-E2, lanes 4, 5,
and 6) or a polyclonal rabbit serum specific for the RV G CD (a-RV-G-
tail, lanes 7, 8, 9).
1-positi
29RHABDOVIRUS-BASED HCV VACCINElater, the mice were bled and E2-specific ELISAs per-
formed. The results in Fig. 6 show that all mice boosted
with the killed virions containing the HCV E2 serocon-
verted, whereas sera from SPBN-E2CD4G primed mice
FIG. 5. Recombinant SPBN-E2CD4G virions as a diagnostic tool.
SPBN-E2RVG virions and incubated with sera from three HCV-positi
(HCV2/RV2). Sera from a RV-vaccinated donor (HCV2/RV1) and HIV-
standard deviations.
FIG. 6. ELISA reactivity of mouse sera against HCV E2. Four groups
of five mice each were immunized with live recombinant RV (SPBN,
SPBN-E2CD4G) as indicated, and 5 weeks after the initial immunization
the mice were boosted twice with killed SPBN-E2CD4 or SPBN virions
as indicated in the figure (Boost). Ten days after the second boost, sera
were collected and analyzed by ELISA. Each bar represents the reac-
tivity of a single mouse serum at a 1:100 serum dilution.that were boosted twice with killed SPBN virions were
negative. These results indicate that two inoculations
with inactivated RV virions containing chimeric HCV E2
are able to induce a potent humoral response directed
against HCV E2. Of note, priming with the recombinant
RV SPBN-E2CD4G did not result in a stronger B cell
response against HCV E2 as seen in unprimed or SPBN
primed mice.
Last, we sought to determine if immunized mice pro-
duced a specific CTL response to HCV E2. In contrast to
HIV-1 gp160, limited information is available for specific
CTL epitopes of HCV glycoproteins in mice and the
responses are mostly weak, even after multiple immuni-
zations. To analyze if a single inoculation with our RV-
based vaccine vehicle expressing the HCV glycoproteins
E1 and E2 is able to induce a cellular response against
HCV E2, 10 female BALB/c mice were vaccinated with
107 ffu of SPBN-E1E2p7 and spleens were harvested 11
weeks later. Splenocytes were cultured and stimulated
for 7 days with an E2-specific peptide (1323), and T-Stim
was added as a source of IL-2. On the day of the assay,
target cells were pulsed both with and without an E2
peptide (1323) and labeled with Cr51. Effectors and tar-
gets were incubated together at several ratios for 4 h.
Figure 7 illustrates an example of one of two indepen-
dent experiments. Specific lysis was detected in a broad
range of a effector:target ratios of 100:1 to 12.5:1. The
observed level of cytolysis was lower than shown previ-
ously for HIV-1 gp160 or Gag, which is probably due to
the used 20mer peptide or a lower frequency of CTL
plates were coated with recombinant HCV E2 derived from purified
ients (HCV1-3), and pooled sera from HCV and RV-negative donors
ve patient (HIV1/RV2) served as controls. The error bars indicate theELISA
ve patmemory cells. Of note, the results indicate that a single
inoculation with recombinant RV expressing HCV-E2 in-
30 SILER ET AL.duces a long-lasting, antigen-specific cellular immune
response.
DISSCUSION
Since the molecular cloning of HCV (Choo et al., 1989),
characterization of its genome has rapidly progressed
but the development of a vaccine against HCV still rep-
resents an impressive challenge for several reasons.
Currently, no method exists to propagate HCV in vitro
(Frolov et al., 1999; Lohmann et al., 2001), which elimi-
nates the possibility of utilizing attenuated or killed HCV
as a vaccine strategy. So far, HCV vaccine studies are
based on recombinant proteins (Choo et al., 1994), na-
ked-DNA-expressing HCV protein(s) (Gordon et al.,
2000), different viral vectors, and prime/boost combina-
tions of DNA and recombinant viruses (Pancholi et al.,
2000; Vidalin et al., 2000). Here, we describe a new
approach for a potential HCV vaccine using both killed
RV particles containing recombinant HCV E2 and live,
replication-competent, RV vaccine strain-based vectors.
For this vaccine approach, three RV were constructed
expressing either the HCV envelope proteins E1 and E2
or a modified version of E2 which lacks 56 amino acids
of its carboxy terminus and contains the human CD4
TMD and the CD4 or RV glycoprotein CD. Our previous
results with RV-based vectors expressing HIV-1 envelope
and Gag protein indicated great promise for recombinant
RVs because these vectors are able to induce both
strong humoral and cellular responses against the ex-
pressed HIV-1 antigens (McGettigan et al., 2001a, 2001b;
Schnell et al., 2000). Because the protective immune
response against HCV is not well defined, we decided in
our initial HCV vaccine approach to focus on both wings
FIG. 7. Immunization of mice with SPBN-E1E2p7 induces HCV E2-
specific CTLs. Six- to eight-week-old female BALB/c mice were immu-
nized ip with 1 3 107 ffu of SPBN-E1E2p7. Spleens were harvested 11
weeks after immunization, and cultured and stimulated with the E2
peptide 1323 and IL-2. A standard chromium release assay was per-
formed 1 week after harvesting, against P815 cells pulsed (1 peptide)
or not (2 peptide) with peptide 1323.of the immune response. Increasing evidence indicates
that cellular immune responses play an important role inself-limited HCV infections and recovery from HCV infec-
tion. In general, both CD41 helper T cells and CD81
cytotoxic T cells seem to be more frequent and stronger
in patients who recover than in patients who develop a
chronic infection (Liang et al., 2000). Moreover, one study
indicated that the number of IFN-g producing cells dur-
ing the first 6 months after the onset of disease is
associated with eradication of the HCV infection (Gru-
ener et al., 2000). Our data indicate that a RV vaccine
vector is able to induce long-lasting CTL responses
against HCV E2, but the specific killing was not as strong
as previously seen for HIV-1 Gag or envelope. Our data
are consistent with those of other groups who used other
HCV vaccine approaches in BALB/c mice and detected
only a low percentage of specific CTLs against HCV E2
(Vidalin et al., 2000). More recently, Gordon et al. (2000)
characterized a new MHC class I E2-specific epitope for
the H-2d haplotype (Gordon et al., 2000), which may be
helpful for further studies of cellular responses against
HCV E2 in BALB/c mice. Of note, our results clearly
indicate that RV-based vectors are potent to induce E2-
specific CTLs. We are currently analyzing our vaccine
approach in an HLA-A2.1 transgenic mouse model that
should allow the use of previously characterized pep-
tides for human HLA-A2.1-restricted CTLs (Battegay et
al., 1995).
In contrast to the cellular response(s), the require-
ments for an HCV-specific humoral response for a HCV
vaccine are more conflicting. Infection of host cells with
enveloped viruses is typically mediated by an interaction
between the viral glycoprotein(s) in the host-cell derived
membrane and a cellular receptor(s) on the host cell.
Previous studies indicate that the hypervariable region 1
(HVR1) of E2 binds to the cellular CD81 molecule of the
host cell (Flint et al., 1999). Hence, it is probable that
host-produced antibodies against E2 would neutralize
the attachment and/or fusion of HCV virions to host cells
during a natural infection. This finding is in conflict with
other results which indicate that the absence of a per-
sisting anti-E2 response correlates with termination of
the infection in chimpanzees and humans (Prince et al.,
1999). On the other hand, passive immunization in chim-
panzees prolonged the incubation period of acute HCV
hepatitis and preincubation of HCV with the serum of a
chronically infected patient prevented infection (Farci et
al., 1994; Krawczynski et al., 1996).
Here, we present a new vaccine strategy to immunize
against HCV. We demonstrated that killed RV particles
containing HCV E2 proteins are able to induce vigorous
B cell responses. The reason for these strong responses
could be that a viral glycoprotein displayed on a viral
particle is more immunogenic than its soluble form. It
has been shown for RV, that soluble G, in contrast to the
virion-associated G, fails to protect from lethal RV chal-
lenge (Dietzschold et al., 1983). Of note, it is not certain
that the observed humoral responses induce by RV viri-
31RHABDOVIRUS-BASED HCV VACCINEons would be protective against HCV infection. There is
evidence that the humoral response(s) against HCV can
create variants, which escape the recognition by anti-
bodies (Farci et al., 1996; Weiner et al., 1992a). A study by
Shimizu et al. (1994) determined the in vitro virus-neu-
tralizing effect of serum of a patient with chronic HCV
during a follow-up of 14 years in comparison to the
infecting virus population. Their findings suggest that
virus-specific antibodies can decrease viral infectivity
and that immune pressure may lead to the evolution of
escape mutants during the course of chronic infection.
Nonetheless, these antibodies were mostly directed
against the HVR1 within the E2 protein. The recent find-
ing that a recombinant HCV containing an HVR1-deleted
E2 protein is still able to cause chronic infection in
chimpanzees (Forns et al., 2000a) indicates that antibod-
ies directed against conserved epitopes outside of the
E2 HVR1 may be more useful to neutralize virus. Further
studies will indicate if killed RV particles containing a
HVR1-deleted E2 protein are still able to induce the same
immune responses as demonstrated for SPBN-E2CD4G
particles.
In summary, we now demonstrate that a recombinant
RV expressing HCV envelope proteins can be generated.
The HCV proteins were stably expressed and induced a
long-lasting cellular response in mice. Moreover, two
vaccinations with killed RV virions containing HCV E2 in
the viral envelope induced a strong E2-specific B cell
response. These results further emphasize the potential
use of RV-based vectors as both live and killed vaccines
for other viral diseases, and ongoing investigations will
indicate if this approach will be useful as preventive or
therapeutic vaccines against HCV and HIV-1.
MATERIALS AND METHODS
Plasmid constuction
All polymerase chain reactions (PCR) were performed
using high-fidelity Vent DNA polymerase (New England
Biolabs, Beverly, MA) to minimize the introduction of
sequence errors. pSBN was described previously
(Schnell et al., 2000) and was the target to introduce a
new single restriction site (PacI, bold) downstream of the
RV G gene by site-directed mutagenesis (GeneEditor)
using the primer 59-GTGAGACCAGACTGTAATTAATTA-
ACGTCCTTTCAACGATCC-39, as indicated by the manu-
facturer (Promega, Madison, WI). The resulting plasmid
was designated pSPBN. The gene encoding the struc-
tural proteins E1E2p7 of HCV was amplified by PCR from
pTM1/E1E2p7 (Michalak et al., 1997), using the forward
primer RP58 59-CTCGAGCGTACGAAAATGAATTCCGAC-
CTCATGG-39 containing a BsiWI site (bold), and the re-
verse primer RP59 59-CGTTAAGCTAGCTCATGCGTAT-
GCCCGCTG-39 containing a NheI (bold) site. The PCR
product was digested with BsiWI and NheI and cloned
into pSPBN, which was digested previously with BsiWIand NheI. The resulting plasmid was entitled pSPBN-
E1E2p7. A recombinant RV expressing the ectodomain
(ED) of HCV E2, lacking 85 amino acids at its C terminus,
and fused to the transmembrane domain (TMD) and
cytoplasmic domain (CD) of human CD4, was amplified
by PCR from pTM1/E2661-CD4 (Cocquerel et al., 1998)
using the forward primer RP 59-CTCGAGCGTACGAAAAT-
GGTCCTGGTAGTGCTG-39 containing a BsiWI site (bold),
and the reverse primer RP 75 59AATTGCTAGCTCAAAT-
GGGGCTACATGTCTTC-39containing a Nhe site (bold).
The PCR product was cloned into pSPBN using the
unique BsiWI and NheI sites resulting in pSPBN-E2CD4.
To construct an RV encoding the HCV E2 ED lacking
85 amino acids at its carboxy terminus and containing
the CD4 TMD and the RV G CD instead of the CD4 CD,
the RV G CD was PCR amplified from pSBN (Schnell
et al., 2000) using the forward primer RP29 59-CCC
GGGTTAACAGAAGAGTCAATC GATCAGAAC-39 (HpaI,
bold) and the reverse primer RP8 59-CCTCTAGATTA-
CAGTCTGGTCTCACCCCC-39 (XbaI, bold). The ED of
HCV E2, lacking its carboxy-terminal 85 amino acids,
fused to the TMD of CD4 was amplified by PCR from
pTM1/E2661-CD4 using the primers RP74 and RP57 59-
AACGAAGAAGATGCCTAGCCC-39. The first PCR product
was digested with HpaI, and ligated to the second one,
and the ligation was PCR reamplified with the primers
RP56 and RP8. The PCR product was cloned utilizing the
BsiWI and XbaI sites into pSPBN previously digested
with BsiWI and NheI. The resulting plasmid was desig-
nated pSPBN-E2CD4G.
Recovery of infectious RV from cDNA
For recovery experiments of the recombinant RVs, the
previously described RV recovery system was used
(Finke and Conzelmann, 1999). Briefly, BSR–T7 cells
(Buchholz et al., 1999) which stably express T7 RNA
polymerase were transfected with 5 mg of full-length RV
cDNA in addition to plasmids encoding for the RV N, P, L,
and G proteins using a Ca2PO4 transfection kit (Strat-
agene, La Jolla, CA) as instructed by the manufacturer.
Three days posttransfection, supernatants were trans-
ferred onto fresh BSR cells and infectious RV was de-
tected an additional 3 days later, by immunostaining with
FITC against the RV-N protein (Centacor Inc.).
Immunofluorescence microscopy
BSR cells were plated in 6-well plates containing cov-
erslips and infected with a m.o.i. of 0.1 for 48 h. Cells
were fixed with 4% paraformaldehyde at room tempera-
ture for 20 min. For internal immunostaining, cells were
permeabilized with 1% Triton in (phosphor-buffered sa-
line) PBS for 5 min at room temperature. Cells were
washed three times with PBS-glycine [10 mM glycine in
PBS (pH 7.4)] and incubated with a monoclonal mouse
antibody directed against HCV E2 (H53, 1:600) for 1 h at
32 SILER ET AL.room temperature and again washed three times with
PBS-glycine. After incubation for another 30 min with
donkey anti-mouse FITC 1:100 (Jackson ImmunoRease-
arch, West Grove, PA) cells were washed three times
with PBS-glycine and analyzed by fluorescence micros-
copy. A FITC-labeled antibody against RV N (Centocor)
was used as described previously (Foley et al., 2000;
Schnell et al., 2000).
Western blotting
BSR cells were infected with a m.o.i. of five for 48 h
and resuspended in lysis buffer [50 mM Tris, pH 7.4/150
mM NaCl/1% NP-40/.1% SDS/ 1X protease inhibitor cock-
tail (Sigma, St. Louis, MO)] on ice for 5 min. The suspen-
sion was transferred to a microcentrifuge tube and spun
for 1 min at 14,000 rpm to remove cell debris. Proteins
were separated by 10% SDS/PAGE and transferred to a
PVDF-Plus membrane (Osmonics, Minnetonka, MN).
Blots were blocked for 1 h [5% dry milk powder in PBS
(pH 7.4)]. After blocking, blots were washed twice using
a 0.1% PBS-Tween-20 solution and incubated with either
monoclonal murine a-E2 antibody (H52, 1:1000) (Flint et
al., 1999), monoclonal murine a-E1 antibody (A4, 1:1000)
(Dubuisson, 2000) or rabbit a-RV-G tail antibody
(1:20,000) (Foley et al., 2000) in 0.1% PBS-Tween for 1 h.
Blots were then washed three times with 0.1% PBS-
Tween. Secondary antibodies of goat a-mouse or donkey
a-rabbit HRP conjugated antibodies (1:5000) (Jackson
ImmunoResearch) were added, and blots were incu-
bated for 1 h. Again, blots were washed three times with
0.1% PBS-Tween and washed once with PBS (pH 7.4).
Chemiluminescence (NEN) was performed as instructed
by manufacturer. For quantification, Hyperfilm ECL film
(Amersham Pharmacia Biotech) was preflashed with a
Sensitize Preflash Unit as indicated by the manufacturer
(Amersham Pharmacia Biotech) and scanned and quan-
tification was performed with NIH Image, version 1.61.
Cytotoxicity assays
Groups of five 6- to 8-week-old female BALB/c mice
(Harlan) were inoculated intraperitoneally (ip) with 107 ffu
of SPBN-E1E2p7. To analyze the induction of specific
CTL response against E2, spleens from three mice of
each group were aseptically removed and combined,
and single cells suspensions were prepared. Red blood
cells were lysed with ACK lysing buffer (BioWhitaker),
splenocytes were washed twice in RPMI-1640 media
containing 10% fetal bovine serum and pulsed with 5
mg/ml peptide1323 [EATYSRCGSGPWITPRCMVD, amino
acids 592–610 in HCV strain 1a], and 10% T-STIM (Col-
laborative Biomedical Products) was added as a source
of interleukin-2 (IL-2). Cytolytic activity of cultured CTLs
was measured by a 4-h assay with 51Cr-labeled P815
target cells. Target cells were prepared by incubating
with 10 mg/ml peptide1323 and 100 mCi 51Cr for 2 h andwashed twice. Target cells were added to effector cells
at various E:T ratios for 4 h. The percent specific 51Cr
release was calculated as 1003 (experimental release—
spontaneous release)/(maximum release—spontaneous
release). Maximum release was determined from superna-
tants of cells that were lysed by the addition of 5% Triton
X-100. Spontaneous release was determined from target
cells incubated without added effector cells.
Immunization for humoral responses
To analyze seroconversion against HCV E2, mice were
immunized ip with 1 3 107 ffu of the respective RV as
indicated. For vaccination with killed RV particles, su-
crose-purified RV (SPBN or SPBN-E2CD4G) was deacti-
vated by incubation with b-propiolactone (1:1000) over-
night at 4°C followed by another incubation at 37°C for
30 min.
Mice were vaccinated/boosted ip with 20 mg of killed
RV particles as indicated in the text and figure legends.
Ten days after the boost, sera were collected and ana-
lyzed by ELISAs for HCV-specific antibodies as de-
scribed below.
Use of recombinant HCV E2 for screening of
seroconversion of vaccinated mice
Ninety-six-well MaxiSorp plates (Nunc) were coated
with recombinant E2 (ImmunoDiagnostic Inc.) in coating
buffer (50 mM Na2CO3, pH 9.6) at a concentration of 2.5
mg/ml and incubated overnight at 4°C. Plates were
washed three times with 0.05% PBS/Tween and blocked
with 5% dry milk powder in PBS for 1 h at room temper-
ature. Mouse sera were diluted in 13 PBS, added to the
plates, and incubated at room temperature for 1 h. After
washing three times with 0.05% PBS/Tween, the second-
ary antibody (goat a-mouse HRP conjugated, Jackson
ImmunoResearch) diluted 1:5000 in 13 PBS was added
and the plates were incubated for 30 min at 37°C. OPD
substrate (Sigma) was added to the plates after washing
three times with 0.05% PBS/Tween. Substrate reaction
was stopped by the addition of 50 ml 2M H2SO4 to each
well. Plates were read at 490 nm.
Use of E2 proteins derived from purified recombinant
virions
Recombinant RVs in the supernatants from SPBN or
SPBN-E2CD4RVG infected BSR cells were sucrose puri-
fied and incubated for 30 min with 1% Triton X-100 in PBS.
RV ribonucleoprotein (RNP) complex was removed by
centrifugation at 16,000 g at 4°C for an hour. Superna-
tants were removed and used directly to coat ELISA
plates or frozen at 80°C. Ninety-six-well MaxiSorp plates
were coated with glycoprotein(s) derived from 25 mg
purified SPBN or SPBN-E2RVG virions for each plate in
coating buffer (50 mM Na2CO3, pH 9.6) and incubated
overnight at 4°C. Plates were washed three times with
33RHABDOVIRUS-BASED HCV VACCINE0.05% PBS/Tween and blocked with 5% dry milk powder
in 13 PBS for 1 h at room temperature. Human sera were
diluted in 13 PBS beginning with a 1:100 dilution, added
to the plates, and incubated at room temperature for 1 h.
Plates were washed three times with 0.05% PBS/Tween
and the secondary antibody (goat a-human horse radish
peroxidase (HRP) conjugated, Jackson ImmunoRe-
search) diluted 1:5000 in PBS was applied, and plates
were incubated at 37°C for 30 min. Plates were washed
three times with 0.05% PBS/Tween, and OPD substrate
(Sigma) was added as instructed by the vendor. Sub-
strate reaction was stopped by the addition of 50 ml 2 M
H2SO4 to each well. Plates were read at 490 nm using a
Bio-Tek ELx800 plate reader.
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